PLEINVUE IN THE CLINICAL PRACTICE OF A PRIVATE HOSPITAL IN NORTHERN MADRID: INITIAL RESULTS OF COLONOSCOPIC PREPARATION

Aims To evaluate the effectiveness, tolerability and safety of IL PEG + ASCORBIC ACID (PLEINVUE) in a real-life setting.

Methods Systematic registration and prospective analysis of patients undergoing screening/diagnostic colonoscopy Bowel cleansing was assessed through the Boston Bowel Preparation Scale (BBPS). Tolerance and side effects were recorded. All patients received bowel preparation with PLEINVUE with a previous 48-hour fiber-free diet followed by 24 hours of clear liquids. We instructed patients to take PLEINVUE as follows: the first dose at 21:00 hours the day before and the second dose between 4–6 hours before colonoscopy, followed by ½ liter of clear liquids after each dose. We advised patients to divide the second dose in four glasses (125 ml) alternating between a glass of preparation and a glass of clear liquids and to drink it slowly for better tolerance.

Results: Between October 2018 and October 2019, 500 patients were included, 52% women and 48% men. Mean age was 58 years (18–83 years), 31.4% ≥ 65 years. Complete bowel preparation was taken by 95% patients. Bowel cleansing by BBPS was ≥ 6 in 94%, ≥ 7 in 77% and ≤ 5 in 6% of patients and in the right colon BBPS = 3 in 47% and BBPS = 2 in 47%. In patients ≥ 65 years BBPS ≥ 6 in 93%, BBPS ≥ 7 in 76% and BBPS ≤ 5 in 5%. Tolerance was good 78%, regular 7% and bad 15%. Vomiting was reported in 15% patients, nausea in 5% without any serious side effects. In those patients reporting vomiting BBPS was ≥ 6 in 89% and BBPS 8–9 in 58%.

Conclusions Colonoscopy preparation with PLEINVUE obtains optimal BBPS levels in total colon cleansing, with an excellent right colon cleansing with only minor side effects. Nausea and vomiting do not seem to affect bowel preparation even in those patients without adequate adhesion.